Targeted alpha therapy in the treatment of ovarian cancer

Reference number 2017-03475
Coordinator VÄSTRA GÖTALANDS LÄNS LANDSTING - Avdelning för onkologi
Funding from Vinnova SEK 2 000 000
Project duration September 2017 - August 2020
Status Ongoing
Venture Eurostars

Purpose and goal

The idea of this project is to develop a targeted alpha-particle radio-immunotherapy (TAT) based on astatine-211 conjugated to the monoclonal antibody (MAb) farletuzumab as a new drug for the treatment of ovarian cancer.

Expected results and effects

Our drug is based on an almost ideal radionuclide for intra cavitary treatment of small tumor aggregates, and thereby has potential to offer treatment of microscopic tumor clusters without significant acute toxicity, which would be a global breakthrough therapy within the field of radioimmunotherapy.

Planned approach and implementation

We will conduct the First-in-Man clinical trial in patients in complete clinical remission after second-line chemotherapy for recurrent ovarian carcinoma. The aim is to study pharmacokinetics (PK) and particularly bio-distribution; as well as safety and toxicity.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.